Hereditary angioedema is an unusual condition that has been associated with a high mortality rate during acute attacks. The disease is felt to have a benign course in pregnancy, but some reports indicate a worsening of attacks in pregnant women. A case of a pregnant woman with known hereditary angioedema presenting with lifethreatening laryngeal oedema is reported, and is followed by a discussion of the disease, its links with sex hormones and a review of the literature.
CASE REPORT A 26-year-old primigravidum woman, pregnant at 25 weeks gestation, was admitted with a two-hour history of a sensation of swelling in her neck. She and her sister had been diagnosed as having type I hereditary angioedema four years previously through family screening following the discovery of a similar diagnosis in her mother. This diagnosis was made on the basis of serum analysis revealing decreased levels of Cl inhibitor (<0.04 g/l; normal range 0.28-0.50 g/l), functional Cl inhibitor (7% ofnormal levels) and C4, the fourth component of complement (<0.06 g/l; normal range 0.2-0.5 g/l) and normal levels of C3, the third component of complement (1.03 g/l; normal range 0.5-1.2 gIl). Her health prior to her pregnancy had been good with only three short-lived episodes ofangioedema affecting her hands alone and one episode of facial swelling following a dental procedure. Since becoming pregnant, there had been an increase in the frequency and duration of the angioedematous episodes, with swelling in her arms, legs and shoulder occurring, on average, once per week.
She was not dyspnoeic and had no foot or arm swelling; her sole complaint was the swelling sensation in her neck which was giving rise to some difficulty in swallowing. On examination she appeared comfortable; her temperature was 36.20 C, with a heart rate of 96 beats per minute, blood pressure of 108/58 mmHg and oxygen saturations of 98% on room air. Cardiovascular and respiratory examinations were normal and abdominal examination was consistent with pregnancy of 25 weeks gestation. There was no evidence of swelling in her throat, neck or peripheries. She was treated with 200 mg of hydrocortisone and 10 mg of chlorpheniramine intravenously and admitted for observation. Three hours later she felt that her breathing had become more difficult. Examination of her oropharynx revealed swelling of the soft palate with the vocal cords moving and the airway intact. Observations and clinical examination otherwise were still normal. A further three hours later she developed respiratory distress with stridor. Examination revealed pharyngeal swelling with the vocal cords viewed only with difficulty. She received one unit of fresh frozen plasma with some improvement of her symptoms and signs and was then given 2000 units ofC 1 inhibitor concentrate, which led to complete resolution within 30 minutes.
She had no further problems while in hospital and was discharged five days later on tranexamic acid. The rest of the pregnancy was uneventful. The delivery was vaginal and uncomplicated with prophylactic administration of C l inhibitor concentrate 1000 units on the day of delivery and the following two days. A healthy male infant was born. To date he has not been screened for hereditary angioedema. DISCUSSION Hereditary angioedema (HAE) is an unusual condition characterised by recurrent episodes of localised, well-circumscribed, non-pitting oedema. It may affect any part of the body, but more commonly involves the extremities, trunk, face, throat and the abdominal viscera where it causes pain. Involvement of the larynx is particularly dangerous, with a high mortality rate.1'2 More recent clinical observations include symptoms of urinary tract infection in women, an increase in spontaneous abortions and premature labour, and more frequently reported heartburn and rheumatic complaints.3 The hereditary nature of the disease was first described by Osler in 1 888,4 and it is transmitted in a Mendelian autosomal dominant manner.5 Investigation of the biochemical abnormality underlying HAE began with the identification and characterisation ofCl -inhibitor.6 C -inhibitor is an a2 globulin that blocks the esterolytic activity of the first component of the classical component pathway.7 It also has inhibitory actions on the fibrinolytic and kallikrein-kinin systems. The mean values ofboth C I inhibitor activity and antigen titres are significantly decreased in normal women using oral contraceptives compared to non-users.29 Familial, oestrogen-linked angioedema attacks not caused by C 1 inhibitor deficiency have also been described. 30 The treatment of HAE has been traditionally divided into three groups i.e. treatment of acute attacks, long-term prophylaxis and short-term prophylaxis. Attempted therapy with adrenaline, antihistaminic agents or corticosteroids has no role or benefit in patients with HAE.8 The mainstay of the treatment of acute episodes of HAB is replacement therapy, successfully used in the therapy of other serum protein deficiencies such as haemophilia and hypogammaglobulinaemia. Infusion of fresh frozen plasma has been shown to be beneficial,3' although concerns exist that it may theoretically worsen the attack.32 Cl1 inhibitor concentrate has also been shown to be safe and effective in the resolution of acute episodes.33 Given in doses of 500 to 1000 units intravenously, oedema begins to resolve within 30 
